Indian equity markets have managed to sustain above the psychologically important 24,000 mark this week, supported by improving sentiment, steady earnings, and hopes of easing geopolitical tensions in West Asia. Market expert Sandip Sabharwal believes the recent rally has been aided by overly negative positioning among investors, creating room for a rebound despite lingering uncertainties.

Speaking to ET Now, Sabharwal said that structurally the market setup remains favourable because sentiment around India had turned excessively pessimistic over the past few weeks. According to him, that negativity itself has created a stronger base for equities to recover.

However, he cautioned that the sustainability of the rally will depend heavily on crude oil prices and developments surrounding the ongoing conflict in West Asia. While recent news flow hints at the possibility of some resolution, he noted that geopolitical situations remain highly volatile and unpredictable.

Sabharwal pointed out that the latest earnings season has been reasonably healthy, which provides downside protection to markets. At the same time, he believes the pace of the market’s upward movement will depend on how quickly geopolitical tensions ease. Instead of a runaway rally, he expects a more gradual and slightly volatile uptrend if uncertainty persists.

Chemical Stocks: Tactical Opportunity Rather Than Structural Revival

Chemical companies have emerged as strong performers after posting robust quarterly numbers. Stocks such as Sudarshan Chemical Industries have reported record topline growth and healthy operating margins, sparking optimism about a broader revival in the sector.
Sabharwal, however, sees the current rally more as a trading opportunity than the beginning of a long-term structural upcycle.
He explained that several chemical manufacturers benefited from a temporary mismatch between rising end-product prices and lower-cost raw material inventories carried earlier. This, in turn, led to a sharp improvement in profitability during the quarter.
According to him, the sector’s recent earnings rebound must also be viewed in the context of the extremely depressed profitability levels witnessed earlier. He stressed that the demand environment has not improved dramatically enough to justify expectations of a sustained multi-year uptrend.

Sabharwal added that many chemical companies expanded aggressively after the post-pandemic profit boom, resulting in an unfavourable global demand-supply balance. While select specialty chemicals may continue to perform well, he does not believe the broader sector is entering a durable long-term bull phase.

OMCs Remain a High-Risk Policy Bet
On oil marketing companies, Sabharwal maintained a cautious stance. Companies such as Indian Oil Corporation, Bharat Petroleum Corporation Limited and Hindustan Petroleum Corporation Limited remain highly sensitive to government policy decisions, making them difficult long-term investments from a shareholder perspective.

He noted that fuel price deregulation has effectively weakened, leaving profitability dependent on government intervention rather than market forces. In such an environment, investors are essentially betting on policy actions rather than business fundamentals.

Still, Sabharwal believes there could be trading opportunities if crude oil prices correct sharply following any diplomatic breakthrough in the Middle East. A significant fall in crude prices could lead to a strong recovery in profitability for OMCs, benefiting investors willing to take short-term exposure.

Rising Fuel Prices Could Trigger Broader Inflation Risks
Sabharwal also warned about the broader economic implications of elevated fuel prices. He highlighted that cost inflation has already started filtering through multiple sectors as companies face rising packaging, logistics, and raw material expenses.

Several companies across industries have reportedly announced price hikes ranging between 5% and 10% to offset cost pressures. Tyre manufacturers, in particular, have seen raw material costs rise sharply, further adding to inflationary stress.

According to Sabharwal, fuel prices have a multiplier effect across the economy because transportation costs influence virtually every segment. While food inflation remains relatively moderate for now, risks remain if weather disruptions linked to El Niño impact rainfall patterns.

He added that moderate inflation is not necessarily negative for corporate earnings because higher prices often support faster topline growth. However, the bigger question is whether companies will be able to protect margins while dealing with elevated input costs.

Sabharwal believes the inflation outlook will ultimately depend on how quickly geopolitical tensions ease, crude prices stabilise, and global shipping and logistics normalise.

Pharma Rally Continues, But Outlook Remains Mixed
Pharmaceutical stocks have also outperformed recently, with the sector gaining nearly 6% this month. Companies including Cipla and Sun Pharmaceutical Industries remain in focus as investors search for defensive opportunities amid global uncertainty.

Sabharwal described the sector’s earnings performance as mixed. While some companies delivered steady results, most failed to significantly outperform expectations. He also noted emerging profitability pressure in certain large pharmaceutical firms.

He pointed out that smaller companies linked to the CDMO theme have reported strong numbers, though he remains cautious due to concerns around cash flow quality in parts of the sector.

Overall, Sabharwal does not see pharma as a secular market-wide theme at present, suggesting that stock-specific opportunities may continue to outperform broader sector bets.

NEW YORK — Rockstar Games will begin marketing “Grand Theft Auto 6” this summer, parent company Take-Two Interactive confirmed Thursday, even as the highly anticipated title’s price remains undisclosed ahead of its scheduled Nov. 19 release.

Take-Two CEO Strauss Zelnick addressed the timing during an interview, pushing back against immediate expectations. “So the next few weeks I don’t think it’ll be summertime yet, but when it’s summertime, Rockstar expects to start marketing ‘GTA 6,’” he said.

The confirmation comes as speculation swirls around one of the most eagerly awaited video game releases in history. “GTA 6” is widely expected to be a massive commercial success, potentially breaking industry sales records upon launch.

Zelnick firmly reiterated the Nov. 19 launch date during Thursday’s earnings discussion. “I think reiterating November 19 as is a launch day today is probably a positive,” he noted, addressing recent rumors of possible delays or pre-order openings.

When asked whether a price announcement would accompany Take-Two’s quarterly earnings release, Zelnick gave a direct response. “No,” he said. “We never make marketing announcements in our analyst calls. Never ever ever.”

The absence of a price tag has not prevented Take-Two from issuing strong financial guidance for the fiscal year ahead. The company projected net revenue between $8 billion and $8.2 billion for the period running April 2026 through March 2027, representing approximately 20% growth over the previous year.

Zelnick explained how such projections are possible without a finalized price point. “So, whenever we put together our guidance, obviously based on our expectations regarding our pipeline, release schedule and pricing, and sometimes our expectations cannot be realized in the fullness of time,” he said. “That could be because the title is delayed, or pricing changes, or unit sales expectations change. But yes, of course, when we build our model, which is used to create guidance, it does have full assumptions in it. Even if we made assumptions, that doesn’t mean that they are set in stone.”

The upcoming marketing campaign is expected to be one of the largest in gaming history. Industry analysts anticipate a multi-month blitz featuring trailers, gameplay reveals, influencer partnerships and extensive social media engagement as Rockstar builds excitement for the title.

“GTA 6” marks the first mainline entry in the Grand Theft Auto series since 2013’s “GTA 5,” which has sold more than 200 million copies worldwide and generated billions in revenue across platforms. The new game is set in a reimagined Vice City inspired by modern-day Miami and is expected to push technical boundaries with its scale, storytelling and online features.

Take-Two reported solid fiscal fourth-quarter results alongside the forward-looking commentary. For the January-March period, the company posted GAAP net revenue of $1.68 billion and a net loss per share of 32 cents. Full-year net bookings reached $6.72 billion, up 19% from the previous year.

The company also highlighted the upcoming September release of “NBA 2K27” as another key title in its pipeline. However, all eyes remain firmly on “GTA 6” as the clear flagship for Take-Two’s growth ambitions.

Investors reacted positively to the earnings and commentary, with shares rising in after-hours trading. The confirmation of summer marketing provides a concrete timeline for what has been one of the most tightly guarded projects in entertainment.

The gaming community has been rife with rumors in recent weeks, including speculation about pre-order availability, potential price points above $70, and even minor delays. Take-Two’s statements appear designed to quell some of that speculation while maintaining strategic ambiguity around pricing and specific campaign details.

Rockstar Games has cultivated a reputation for meticulous development and surprise reveals. The studio’s marketing approach for previous titles has involved carefully timed trailers that generate massive online engagement and media coverage. A similar strategy is widely expected for “GTA 6.”

Analysts estimate the game could generate more than $2 billion in first-year sales, potentially making it one of the highest-grossing entertainment launches ever. Its success will be critical for Take-Two as it navigates a competitive landscape that includes major releases from competitors like Ubisoft, Electronic Arts and Microsoft’s Activision Blizzard.

The summer marketing push will likely begin in earnest during July or August, potentially coinciding with major gaming events or standalone digital showcases. Fans can expect the first official trailer or deep-dive gameplay footage to drop during this period.

Pricing remains a key unknown. While most major releases now carry a $70 suggested retail price, “GTA 6” could command a premium given its scope and the franchise’s cultural significance. Some analysts have speculated on a $70-$80 range for standard editions, with higher tiers for special or collector’s versions.

Take-Two’s ability to provide full-year guidance without revealing the price demonstrates the company’s confidence in its internal modeling and long-term pipeline. The fiscal 2027 outlook suggests management expects “GTA 6” to be a significant driver of growth.

Beyond the single-player campaign, “GTA Online” successor features are expected to play a major role in long-term monetization. The online component of “GTA 5” has proven extraordinarily durable, generating ongoing revenue years after launch.

As summer approaches, anticipation continues to build. The confirmation of a marketing start provides a focal point for fans and industry observers tracking every hint and leak about the game.

Take-Two’s disciplined approach to communication has served it well in the past, allowing Rockstar to maintain creative control and maximize impact when campaigns finally begin. This summer’s rollout will likely follow that proven playbook.

For now, gamers must wait a few more weeks for official summer to arrive and the marketing machine to kick into gear. When it does, “GTA 6” is expected to dominate entertainment conversations for months leading up to its November debut.

The Nov. 19 release date positions the game perfectly for holiday season sales, traditionally the strongest period for video game revenue. Strong pre-order numbers and launch-weekend performance could set new benchmarks for the industry.

As one of the most culturally significant entertainment franchises, “GTA 6” carries expectations that extend far beyond financial performance. Its storytelling, satire and open-world design have influenced generations of players and developers alike.

Take-Two’s latest update provides welcome clarity amid swirling rumors while preserving the mystery that has kept fans engaged for years. With marketing on the horizon and the release date locked in, the countdown to one of gaming’s biggest moments has officially begun.

SYDNEY — Shares in Fisher & Paykel Healthcare Corporation Ltd jumped more than 9% on Tuesday after the New Zealand medical device maker reported robust full-year results and reaffirmed confidence in its growth trajectory amid rising global demand for respiratory care products.

The stock climbed $2.52, or 9.15%, to close at $30.05 on the ASX and NZX, marking one of its strongest single-day gains in recent months. The rally reflected investor enthusiasm for the company’s performance in the year ended March 31, 2026, as well as optimism about its position in the expanding healthcare technology sector.

Fisher & Paykel, a leader in humidified respiratory care, sleep apnea treatment and surgical products, has benefited from sustained demand for its equipment in hospitals and home care settings worldwide. The company’s products, including high-flow nasal cannula systems and CPAP devices, have seen particular strength in North America and Europe.

Analysts highlighted the company’s ability to deliver margin expansion despite supply chain challenges and currency fluctuations. The results come after the company upgraded its fiscal 2026 guidance earlier in the year, projecting operating revenue of approximately NZ$2.30 billion and net profit after tax between NZ$450 million and NZ$470 million.

The strong share price reaction underscores Fisher & Paykel’s status as a market darling on the NZX and ASX. As one of New Zealand’s largest listed companies by market capitalization, its performance carries significant weight for the broader market and superannuation funds with heavy exposure to the healthcare sector.

Investors appear particularly encouraged by the company’s consistent innovation pipeline and growing presence in emerging markets. Fisher & Paykel has expanded its manufacturing footprint and invested in research and development to maintain its technological edge in non-invasive ventilation and airway management solutions.

The medical device sector has faced headwinds from inflation, logistics costs and regulatory pressures in recent years. Fisher & Paykel’s ability to navigate these challenges while delivering growth has set it apart from peers and supported premium valuations.

Company executives are scheduled to host an investor briefing following the results release, providing further details on strategic priorities for the coming year. Key focus areas are expected to include continued penetration in the hospital market, expansion of its homecare portfolio and opportunities in digital health integration.

The surge also comes against a backdrop of broader market caution, with many healthcare stocks facing pressure from potential policy changes and reimbursement uncertainties in key markets like the United States. Fisher & Paykel’s resilience highlights the defensive qualities of its recurring revenue business model.

Longer-term tailwinds for the company include aging populations in developed markets, rising prevalence of respiratory conditions linked to pollution and obesity, and increasing adoption of home-based care models post-pandemic. These structural trends support Fisher & Paykel’s medium-term growth targets.

Analysts have generally maintained positive outlooks on the stock. JPMorgan initiated coverage with an Overweight rating and a price target of NZ$37.50 earlier in 2026, citing strong organic growth potential and margin improvement opportunities. Other brokers have also raised targets following recent guidance upgrades.

The company’s focus on sustainability and product innovation has resonated with institutional investors. Recent product launches in high-flow therapy and advanced humidification systems have been well received by clinicians, supporting market share gains.

Geographically, North America remains the largest contributor to revenue, followed by Europe and Asia-Pacific. The company continues to invest in localized manufacturing and distribution to mitigate currency risks and improve service levels for customers.

Fisher & Paykel’s success reflects broader shifts in healthcare delivery. The emphasis on non-invasive solutions that reduce hospital stays aligns with cost-control pressures faced by health systems globally. Its products have played important roles in managing conditions ranging from sleep apnea to chronic obstructive pulmonary disease.

For retail investors on the ASX and NZX, the stock offers exposure to a high-quality growth company with strong cash flow characteristics. Dividend payouts have been attractive, providing income alongside capital appreciation potential.

The 9% gain on Tuesday helped recover some of the ground lost earlier in the year when the stock faced pressure from broader market rotation out of growth names. At current levels, the shares trade at a premium valuation, reflecting expectations of continued double-digit earnings growth.

Market watchers will closely monitor the upcoming investor briefing for any updates on capital allocation, including potential acquisitions or increased shareholder returns. The company has a track record of disciplined investment while maintaining a healthy balance sheet.

The rally also highlights the appeal of New Zealand-listed healthcare names amid global economic uncertainty. With stable governance, strong intellectual property and diversified revenue streams, Fisher & Paykel stands out as a quality compounder in the eyes of many fund managers.

Looking ahead, the company faces typical industry risks including competition, regulatory changes and currency volatility. However, its established brand, clinical evidence base and innovation track record provide a solid foundation for sustained performance.

Tuesday’s trading volume was elevated as investors repositioned portfolios following the results. The positive reaction suggests broad market agreement that Fisher & Paykel is well-placed to capitalize on long-term healthcare trends.

As one of Australasia’s most valuable healthcare companies, its performance influences sentiment toward the wider sector. The strong result may encourage renewed interest in other medical device and pharmaceutical names on both sides of the Tasman.

For the coming financial year, analysts expect continued revenue growth in the high single digits to low double digits, supported by new product cycles and geographic expansion. Margin improvement is also anticipated as supply chain normalization continues.

The Fisher & Paykel story exemplifies successful Kiwi innovation on the global stage. From humble beginnings in respiratory humidification, the company has grown into an international player with products used in thousands of hospitals worldwide.

Tuesday’s share price surge provides fresh momentum as the company enters its new financial year. With a clear strategy and strong execution, Fisher & Paykel Healthcare appears positioned to deliver further value for shareholders in the years ahead.

A company of Manulife Investment Management, John Hancock Investment Management serves investors through a unique multimanager approach, complementing our extensive in-house capabilities with an unrivaled network of specialized asset managers, backed by some of the most rigorous investment oversight in the industry. The result is a diverse lineup of time-tested investments from a premier asset manager with a heritage of financial stewardship. Note: This account is not managed or monitored by John Hancock Investment Management, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use John Hancock Investment Management’s official channels.